Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for rare bone disease pain?

NCT ID NCT01791842

Disease control Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called tocilizumab for people with fibrous dysplasia of bone who still had pain after standard treatment. The drug blocks a protein linked to bone breakdown. Nineteen adults participated in this small, early-stage trial to see if the drug could reduce bone pain and slow bone damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

19 people

The number who actually took part.

Started

May 2013

Finished

Jun 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * fibrous dysplasia of bone * previously treated with IV bisphosphonates * persistent bone pain and increased bone remodeling Exclusion Criteria: * Chronic renal failure * serious infectious diseases * liver enzymes abnormality * pregnancy * dyslipidemia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fibrous dysplasia of bone are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fibrous dysplasia polyostotic fibrous dysplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fibrous dysplasia of bone

Contacts and locations

Locations

  • Service de Rhumatologie, Groupe Hospitalier Pellegrin

    Bordeaux, France

  • Service de rhumatologie, Hopital Edouard Herriot, HCL

    Lyon, 69003, France

  • Service de rhumatologie, Hôpital Lariboisière

    Paris, 75010, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.